For the second year running, ControlCheck takes top marks in all product categories and receives a score of 90 out of 100

WASHINGTON–(BUSINESS WIRE)–BLuesight, the leading automation vendor in Medication Intelligence solutions that brings cost savings, efficiency, and patient safety to hospitals, today announced its ControlCheck product won Best in KLAS for Drug Diversion Monitoring in the 2021 Best in KLAS Report. Created by industry-leading healthcare technology analyst firm KLAS Research, the Best in KLAS report celebrates technology solutions that stand out from the competition in various categories.

“We are humbled and proud to have ControlCheck celebrated in the marketplace during a trying and difficult year for healthcare workers everywhere,” said Kevin MacDonald, CEO and Co-Founder of Bluesight.

“We are delighted to win Best in KLAS for Drug Diversion Monitoring for the second year in a row,” said Kevin MacDonald, CEO and Co-Founder of Bluesight. “Our growing community of ControlCheck customers is helping combat the opioid epidemic in real-time. Sadly, the COVID-19 pandemic has only exacerbated the opioid epidemic with overdose deaths increasing to all-time high levels. We are humbled and proud to have ControlCheck celebrated in the marketplace during a trying and difficult year for healthcare workers everywhere. It is wonderful to know ControlCheck hospital users all over the country were comforted in 2020 knowing they can prevent drug diversion and assist struggling team members in getting the help they need.”

KLAS President Adam Gale provides some background on the Best in KLAS award. “Each year, thousands of healthcare professionals across the globe take the time to share their voice with KLAS. They know that sharing their perspective helps vendors to improve and helps their peers make better decisions. These conversations are a constant reminder to me of how necessary accurate, honest, and impartial reporting is in the healthcare industry. The Best in KLAS report and the awards it contains set the standard of excellence for software and services firms. Vendors who win the title of ‘Best in KLAS’ should celebrate and remember that providers now accept only the best from their products and services. The Best in KLAS award serves as a signal to provider and payer organizations that they should expect excellence from the winning vendors.”

For the report, 39 ControlCheck users were interviewed about their experience with the product, a larger sample size than any other evaluated vendor. The feedback highlighted ControlCheck’s industry-leading features. Providers commented that ControlCheck performed hours and hours of manual audits and data analysis automatically, provided a framework for cohesive collaboration between nursing and pharmacy, and, most importantly, clearly identified providers with anomalous behavior patterns at a higher risk of diverting medications, without creating extraneous data points to sift through. Bluesight’s comprehensive product support and implementation services were also celebrated in provider feedback.

One director of pharmacy highlighted ControlCheck’s Investigation Portfolios feature that creates a repeatable and robust cross-departmental investigation framework when suspected diversion arises. “The fact that Bluesight[’s ControlCheck] actually has an investigation workflow sets them apart from other vendors. The solution is organized well with checklists and workflows that we can build into it. Their functionality is far above the functionality of any other vendors’ products we have seen.”

Additionally, one manager highlighted the industry-leading support and feature collaboration ControlCheck users can expect from Bluesight, especially during the COVID-19 pandemic when providers continue to be stretched thin and risk for diversion only increases. “The vendor is ahead of the curve in terms of integration. We are able to add new drugs frequently. During the COVID-19 crisis, the vendor was instrumental by adding drugs to the system because we saw a huge diversion in our sister hospital. The vendor is able to pivot really quickly and integrate things into the system without making a big push for us.”

The full 2021 Best in KLAS report is available here: https://klasresearch.com/report/best-in-klas-2021/1820.

The 2021 Best in KLAS segment for Drug Diversion Monitoring is available here: https://klasresearch.com/best-in-klas-ranking/drug-diversion-monitoring/2021/365.

To learn more about Kit Check’s solutions, please visit www.kitcheck.com.

To learn more about KLAS, please visit http://www.klasresearch.com.